Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Earnings for Aethlon Medical, Inc. (AEMD)
Earnings in 2024 (TTM): $-12,208,174
According to Aethlon Medical, Inc.'s latest financial reports the company's current earnings (TTM) are $-12,208,174. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Aethlon Medical, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-12,208,174 | $-12,208,174 |
| 2023 | $-12,029,786 | $-12,029,786 |
| 2022 | $-10,420,885 | $-10,416,091 |
| 2021 | $-7,891,499 | $-7,886,709 |
| 2020 | $-6,380,041 | $-6,373,948 |
| 2019 | $-6,219,504 | $-6,194,719 |
| 2018 | $-5,699,837 | $-5,679,558 |
| 2017 | $-7,306,726 | $-7,276,113 |
| 2016 | $-4,958,616 | $-4,872,329 |
| 2015 | $-6,979,494 | $-6,797,157 |
| 2014 | $-13,438,962 | $-13,357,232 |
| 2013 | $-4,892,040 | $-4,892,040 |
| 2012 | $-8,111,340,000 | $-8,111,340 |
| 2011 | $-5,711,435,000 | $-5,711,435 |
| 2010 | $-3,012,153 | $-4,573,315 |
| 2009 | $-4,314,066 | $-6,084,158 |
| 2008 | $-2,820,777 | $-4,140,264 |
| 2007 | $-5,633,577 | $-6,024,545 |
| 2006 | $-2,551,608 | $-2,920,183 |
| 2005 | $ | $-2,096,951 |
| 2004 | $ | $-1,518,798 |
| 2003 | $-1,971,385 | $-2,461,116 |
| 2002 | $-3,995,910 | $-3,995,910 |
| 2001 | $-4,423,073 | $-4,423,073 |
| 2000 | $-1,294,218 | $-1,299,382 |
| 1999 | $-352,054 | $-352,679 |
| 1998 | $ | $-3,599 |
| 1997 | $ | $-1,534 |